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Abstract:  Alzheimer’s disease (AD) is characterized clinically by dementia and 
pathologically by two hallmark lesions, senile plaques and neurofibrillary tangles. About a 
quarter century ago these hallmark lesions were purified and their protein constituents 
identified, precipitating an avalanche of molecular studies as well as substantial optimism 
about successful therapeutic intervention. In 2009, we now have copious knowledge on the 
biochemical cascades that produce these proteins, the different modifications and forms in 
which these proteins exist, and the ability to selectively target these proteins for therapeutic 
intervention on an experimental basis. At the same time, there has been no discernible 
alteration in the natural course of AD in humans. While it may be that the complexity of 
AD will exceed our capacity to make significant treatment progress for decades or more, a 
paradigm shift from the reductionism that defines amyloid-β and tau hypotheses, to one 
that more accurately reflects the meaning of neuropathological changes, may be warranted. 
We and others have demonstrated that AD pathology is a manifestation of cellular 
adaptation, specifically as a defense against oxidative injury. As such, AD pathology is 
therefore a host response rather than a manifestation of cytotoxic protein injury, and is 
unlikely to be a fruitful target for therapeutic intervention. An “expansionist” view of the 
disease, we believe, with oxidative stress as a pleiotropic and upstream process, more aptly 
describes the relationship between various and numerous molecular alterations and   
clinical disease.  
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1. Introduction 
 
“Researchers have already cast much darkness on the subject, and if they continue their 
investigations, we shall soon know nothing at all about it." - Mark Twain 
 
Alzheimer’s disease (AD) is a heterogeneous condition, differing in age at onset, clinical 
symptomatology, extent and distribution of pathological changes, presence or absence of germline 
mutations, presence or absence of polymorphic susceptibility alleles, and presence or absence of a long 
list of risk factors. This being the case, it is predictable that numerous hypotheses with “treatment 
implications” have been suggested, and perhaps equally so that none of these hypotheses have resulted 
in a tangible treatment benefit. The failure of the medical science community to impact the natural 
course of disease may reflect the complexity of AD, although at some point it becomes reasonable to 
question the prevailing paradigms and suggest a fundamental re-organization of the thought processes 
to more directly address cause, and avoid copious and detailed characterizations of epiphenomena [1].  
At present, dominant hypotheses equate the soluble protein constituents of insoluble pathological 
lesions with toxicity. For example, AD brains accumulate neurofibrillary tangles, neurofibrillary 
tangles contain phosphorylated tau, phosphorylated tau exists in a soluble intermediate form that is 
toxic to synapses, phosphorylated tau thus is a product of a pathological cascade that is inherently 
deleterious, and that pathological cascade, if left unchecked, causes neurodegeneration [2]. 
Alternatively, AD brains accumulate senile plaques, senile plaques contain amyloid-β protein (Aβ), Aβ 
protein exists in soluble intermediate form that is toxic to synapses, Aβ is therefore a product of a 
pathological cascade that is inherently deleterious, etc. [3]. Whereas these approaches have a 
reductionist appeal and are easily understood, they are also presumptuous. Of concern is the poor 
correlation of these molecules with disease and the increasing literature demonstrating their role in 
cellular adaptation and survival [4]. 
In this review, we discuss the molecular pathophysiology of two major proteins implicated in AD 
pathogenesis, as well as the role of oxidative stress, and the concept of pathology (and associated 
proteins) as a downstream response in neurodegenerative disease.  
 
2. Amyloid-β 
 
Aβ was initially identified through purification of structural pathology-amyloid plaque cores and 
blood vessels involved by cerebral amyloid angiopathy [5,6]. Identification of Aβ as a metabolic 
product of amyloid-β protein precursor (AβPP), its position on chromosome 21, and the identification 
of familial AD kindreds carrying pathogenic AβPP mutations solidified Aβ as a putative central 
molecule in AD pathogenesis.  
While the Aβ cascade concept has shifted somewhat in recent years to reflect soluble Aβ species 
and targeting of the synapse, it is worth remembering that the current, extensive knowledge of Aβ was 
derived from the targeting of insoluble pathological lesions, lesions that were, in turn, targeted because 
they were presumed toxic [1]. The poor correlation between insoluble lesions and disease has rendered 
the microscopic pathology partly decorative and non-toxic epiphenomena, so the central importance Int. J. Mol. Sci. 2009, 10                 
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currently of soluble species, being the product of non-toxic insoluble epiphenomena, is   
remarkably fortuitous.  
Aβ is derived from the much larger AβPP, an integral type I membrane glycoprotein encoded in 19 
exons on chromosome 21q21 (reviewed in [7-9]. When fully expressed, AβPP contains a short 
cytoplasmic tail, a transmembrane portion, and a relative large extracellular domain, although in 
culture only about 10% of newly synthesized AβPP molecules reach the cell surface. AβPP exists as 
multiple alternatively spliced isoforms, with three predominating: two isoforms, AβPP770/751 contain 
the so-called Kunitz protease inhibitor domain (exon 7) within the extracellular portion and are 
considered the predominant forms in non-neuronal cells, whereas AβPP695 is devoid of the Kunitz 
protease inhibitor domain and is the predominant neuronal form.  
Enzyme cleavage is said to result in amyloidogenic and non-amyloidogenic fragments, depending 
on whether or not processing results in the Aβ protein. Inherent in the term “amyloidogenic” is a 
process that is fundamentally pathological, although it is worth noting that Aβ synthesis, including the 
so-called pathogenic Aβ, Aβ1-42, is a physiological process, being synthesized and secreted throughout 
life. In fact, Aβ is detected in healthy controls, as well as AD patients, in cerebrospinal fluid and 
plasma [10].  
Cleavage of AβPP by either α-secretase or β-secretase produces soluble N-terminal fragments 
AβPP, and C83 and C99 membrane-bound C-terminal fragments, respectively. Further cleavage by γ-
secretase leads to the release and secretion of non-pathogenic p3 peptide (previous α-secretase 
cleavage) and Aβ (previous β-secretase cleavage). Depending on the precise site of γ-secretase 
cleavage, different lengths of Aβ are produced, varying from 38 to 43 amino acids. The 42 amino acid 
form, Aβ42, has a greater tendency to form fibrils in vitro compared to other forms, and therefore 
comprises the core of the amyloid cascade hypothesis.  
The combination of β-secretase and γ-secretase cleavage, resulting in the Aβ peptide, was 
established early on in the study of Aβ metabolism, while the elucidation of the constituents and cell 
biology of γ-secretase has proven a challenge, owing to substantial complexity and the interplay with 
presenilins, PS1 and PS2. The presenilins, initially identified through linkage to early onset familial 
AD with apparent increased Aβ42 [11-13], are two candidates for the components of the γ-secretase 
complex [14].  
Despite the presumption of presenilin as an important component of the multimeric secretase 
complex, the biochemical mechanism of presenilin action is unknown. During development, 
presenilins appear to cleave a transmembrane protein called Notch, which in turn is a transcriptional 
activator of genes involved in cellular differentiation [15]. PS1 and PS2 have been found to be 
involved in a range of biological processes, including cell adhesion, G-protein mediated signal 
transduction, the unfolded protein response [16-19]. Nicastrin has also been shown to interact strongly 
with the presenilins and appears to be required for normal Notch signaling in Caenorhabditis  
elegans [20].  
AβPP cleavage with generation of Aβ fragments is also complicated by AβPP processing as a 
function of cellular subcompartment in which it occurs. Once at the cell surface, AβPP is 
proteolytically processed, primarily by α-secretases, resulting in shedding of the majority of the 
extracellular domain within minutes of reaching the plasma membrane. Rapid and efficient 
internalization is mediated by a “YENPTY” internalization motif near the carboxy terminus of the Int. J. Mol. Sci. 2009, 10                 
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AβPP molecule [7]. Interestingly, YENPTY mutations decrease Aβ generation. Once endocytosed, 
AβPP may be recycled to the cell surface, degraded, or further processed. β-site AβPP cleaving 
enzyme-1 (BACE1) appears to act on AβPP in late Golgi/TGN and endosomes, as supported by the 
acidic optimal pH of BACE1. γ-secretase complex activity on the other hand apparently takes place in 
multiple cellular compartments including endoplasmic reticulum, Golgi, and the plasma membrane, 
although the latter is thought to comprise only a small fraction of the γ-secretase activity.  
The cellular function of AβPP is incompletely resolved. One candidate ligand, secreted neuronal 
protein F-spondin believed to function in neuronal sprouting, binds AβPP as well as APLP-1 and 
APLP-2, possibly interfering with β-secretase cleavage and cytoplasmic domain mediated cell 
signaling [8]. AβPP may also serve as a receptor for intracellular transport of synaptic vesicles through 
interaction with kinesin and microtubules [21]. Both AβPP and the low density lipoprotein receptor-
related protein bind the adaptor protein Fe65 via their cytoplasmic domains which increases AβPP 
proteolytic processing, suggesting a relationship between the two proteins [22]. Both LDL receptor-
related protein and AβPP are also γ-secretase substrates once their extracellular domains are removed. 
Perhaps the most important role of AβPP and Aβ is that of an antioxidant in an organ system that is 
particularly vulnerable to oxidative stress (see below). 
In short according to the amyloid cascade hypothesis, the fundamentally toxic Aβ42, otherwise a 
product of normal cellular metabolism, is overproduced in disease and causes neurodegeneration. 
Support for this concept comes principally from Mendelian diseases with pathogenic AβPP mutations 
leading to extensive Aβ deposits and early onset disease, presenilin mutation cases that increase the 
Aβ42/40 ratio, and in vitro toxicity of Aβ42 peptides. Whether Aβ42 is toxic in vivo remains to be 
elucidated, whereas significant evidence for the role of Aβ42 in neuroprotection has been   
demonstrated [4]. 
 
2.1. Aβ and clinical disease 
 
The relationship between Aβ pathology and disease has been the subject of a number of studies and 
is well known to be imprecise at best [1]. An early study in the 1960s that showed an overall trend 
toward increased disease severity with plaque burden [23] has been refuted in a number of subsequent 
studies [24-26]. At present, it is generally accepted that amyloid burden overall correlates poorly with 
disease severity, whereas the distribution of Aβ tends to be diffuse throughout the neocortex with little 
region specificity [25]. Diffuse deposits of amyloid also occur in the striatum and cerebellar cortex 
[27,28], in the absence of overt loss of function subserved by those regions, and in the absence of 
neurofibrillary degeneration, either in the form of dystrophic neurites or neurofibrillary tangles. 
Relative to neocortical Aβ, the medial temporal allocortical region which among other things 
subserves episodic declarative memory, shows decreased Aβ [25], a finding that is often overlooked in 
studies of synaptic function in the hippocampus. Given the putative role of apolipoprotein E (ApoE) in 
facilitating fibrillogenesis, it is also interesting that the extent of neocortical Aβ deposits does not 
correlate with the various ApoE alleles, including ε4 [29].  
The lack of eloquence of Aβ deposition with respect to clinical signs has led to the suggestion that 
the more region specific tau pathology is a form of retrograde degeneration, i.e. that the close 
correlation with neurofibrillary degeneration in the temporal allo- and periallocortex, and memory loss, Int. J. Mol. Sci. 2009, 10                 
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may be due to Aβ deposits elsewhere, to which phospho-tau-altered neurons are projecting [30]. The 
opposite sequence has also been suggested with regard to degeneration of the basal nucleus of Meynert 
and the locus ceruleus—that these regions degenerate early and project to neocortical areas that 
subsequently develop amyloid deposits [31]. These interesting concepts are as yet unproven, as is the 
possibility of a temporal and spatial disconnect between Aβ and tau deposits [32], but taken together, 
studies of regional distribution of proteinaceous deposits highlight the problematic nature of 
reductionist theories in conditions as complex as AD.  
 
2.2. Aβ attack on the synapse 
 
Synapse loss has long been a well known, yet not widely studied, structural condition tightly 
associated with the cognitive decline in AD. Early work documented a categorical relationship with 
dementia [33], a relationship which more recently was found to parallel cases of mild AD [34]. In 
addition, cases assessed to have mild cognitive impairment (MCI) show an intermediate level of 
synapse loss, again reflecting MCI as preempting the development of AD. In these studies, however, 
synapse loss showed no relation to senile plaque density or to Braak stage. A relatively new paradigm 
that is more functional than structural has emerged, rendering moot, presumably, the anatomically 
imprecise and poorly correlated Aβ deposits. It is now suggested that soluble, low-n Aβ oligomers, 
identified by high speed centrifugation and Western blotting of the supernatant, cause synaptic damage 
and functional neurologic deficits [3]. Experimental studies involving injection of conditioned 
medium, derived from oligomer-secreting AβPP V717F Chinese hamster ovary cells, into rat lateral 
ventricle, demonstrated alterations in long term potentiation (LTP) that was related to low-n oligomers 
per se and not monomers [35]. LTP alteration was also shown in vitro in hippocampal mouse slices, 
along with concomitant changes in cell cycle signaling cascades and behavioral abnormalities. These 
models provide useful platforms for analyzing the Aβ-mediated synapse loss, which may be indicative 
of dysfunction of NMDA-type glutamate receptor activation. Therapeutics blocking this activation 
directly affect the synaptic profile, as does preventing the formation of amyloid oligomers [36]. These 
studies support the Aβ immunization strategies that, so far, have been ineffective. On the other hand, 
the occurrence of an untoward T-cell driven meningoencephalitis in an initial clinical trial is well 
known [37].  
 
3. Phosphorylated Tau 
 
3.1. The neurofibrillary tangle 
 
While plaques were a known accompaniment of senile dementia in the late 1800s, the first 
description of the neurofibrillary tangle in 1907 can be attributed to Alzheimer [38]. It is also 
interesting to note that Alzheimer devoted ten sentences and two paragraphs to his initial description of 
the neurofibrillary tangle, compared to only two sentences to the senile plaque [38,39]; this, and the 
fact that plaques were a known component of senile dementia at that time [40], suggests that the 
neurofibrillary tangle was the more intriguing lesion. Nevertheless, in spite of copious literature 
written by Alzheimer and his contemporaries, it is difficult to find firm allusions to the cause of the Int. J. Mol. Sci. 2009, 10                 
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basic disease process. Rather, the importance and controversy rested for the most part in whether this 
condition affecting a relatively young patient represented a new disease or, instead, was a form of 
senile dementia with early onset [41].  
Not long after the purification of amyloid deposits and the identification of the Aβ protein, 
neurofibrillary tangles were purified and the microtubule associated protein tau determined as the 
major protein component [42]. The enthusiasm for tau phosphorylation as a primary process in AD 
was however blunted by the absence of genetic linkage, which has forever relegated pathological tau 
events to a downstream position on the popular algorithms. Instead, germline tau mutations are more 
closely related to the frontotemporal dementia phenotype [43].  
 
3.2. Tau protein 
 
Since the identification of tau as the major component of neurofibrillary pathology, knowledge of 
tau has expanded considerably. We now know that the tau gene is comprised of over 100 kb and 
contains 16 exons (reviewed in [44]). Upstream of the first exon are consensus binding sites for 
transcription factors such as AP2 and SP1. Alternative splicing of tau nuclear RNA transcribed in the 
adult brain on exons two, three, and ten, results in six tau isoforms. The isoforms differ in the presence 
of either three of four peptide repeats of 31 or 32 residues in the C termimal region encoded on exon 
10. This peptide repeat region comprises the microtubule binding domain. Tau isoforms also differ in 
the expression of zero, one, or two inserts encoded on exons two and three. The relative amounts of 
these tau isoforms as well as their phosphorylation status changes during development; 3 repeat tau 
with no inserts is expressed in the fetus and early postnatal infant, while heterogeneous isoforms are 
expressed in the adult brain. This switch in RNA splicing also corresponds to a reduction in tau 
phosphorylation. Tau is relatively abundant in neurons but is present in all nucleated cells and 
functions physiologically to bind microtubules and stabilize microtubule assembly for polymerization.  
In disease, tau is abnormally hyperphosphorylated at proline directed serine/threonine 
phosphorylation sites [44-46], including Ser-202/Thr-205 (AT8 site), Ser-214 and/or Ser-212 (AT100 
site), Thr-231 and/or Ser-235 (TG3 site), and Ser-396/Ser-404 (PHF-1 site). In addition, alternative tau 
splicing as noted above has a tendency to differ depending on pathological phenotype, such that tau 
accumulation in AD is a mixture of 3R and 4R tau, Pick disease tends to be 3R tau, corticobasal 
degeneration and progressive supranuclear palsy tends to be 4R tau, and so-called argyrophilic grain 
disease accumulates small inclusions comprised of 3R tau. The general term “tauopathy” is thus used 
as a means of broad classification of neurodegenerative diseases.  
 
3.3. Tau and clinical disease 
 
In spite of the fact that tau pathophysiology is generally considered a secondary or downstream 
phenomenon, it is nevertheless interesting that neurofibrillary pathology correlates closely with clinical 
signs [26]. The eloquence of phosphorylated tau deposition, for example its proclivity for the memory 
circuitry in the medial temporal lobe perirhinal, entorhinal, and hippocampal regions early in the 
disease and in the setting of MCI, indicates a much closer functional relationship to disease than Aβ, at 
least in terms of spatial distribution of insoluble deposits [47,48]. It is also remarkable that neocortical Int. J. Mol. Sci. 2009, 10                 
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neurofibrillary pathology is virtually always associated with clinical signs of AD [48], whereas 
extensive neocortical Aβ deposits are often seen in the absence of significant cognitive impairment or 
evidence of neuronal loss in the elderly population [24]. Therefore, whereas the pathology of normal 
aging and that of AD differ more quantitatively than qualitatively, heavy tau “burden” is generally 
incompatible with preserved cerebral function, while heavy amyloid burden is often tolerated.  
 
3.4. Tau attack on the synapse 
 
Not to be outdone, the role of phosphorylated tau in functional disease is progressing in a manner 
very much similar to Aβ. Once considered toxic due to its insolubility, recent studies indicate that 
insoluble tau accumulation is somewhat benign and instead implicate soluble, oligomeric phospho-tau 
intermediates, and indeed their effect on the synapse, as an underlying theme. Experimental support 
includes a transgenic model in which mice expressing a repressible human tau show behavioral 
improvements with tau suppression yet continue to accumulate neurofibrillary tangles, indicating that 
neurofibrillary tangles themselves are insufficient to cause cognitive decline or neuronal death [49]. In 
another AD-like model, axonal pathology with accumulation of tau preceded plaque deposition [50]. 
Studies of a P301S tauopathy model demonstrated microglial activation and synapse loss prior to 
neurofibrillary tangle formation implicating inflammatory response as a possible therapeutic target for 
maintaining synapse well-being [51]. These studies, along with others inhibiting protein phosphatases 
which also result in synapse loss as a result of increased tau phosphorylation [52] indicate that 
neurofibrillary tangle formation is a late stage non-toxic event and directing attention toward upstream 
soluble tau intermediates.  
 
4. Oxidative Stress: An “Expansionist” Approach 
 
The concept of oxidative stress runs counter to the sensibilities of the practicing neuropathologist 
because it cannot be directly visualized. An unpaired electron orbiting an atom of oxygen cannot be 
placed on a glass slide or an electron microscopy grid, and photographed or otherwise imaged. This 
may explain at least in part its general lesser acceptance as a pathogenic process compared to proteins 
derived from identifiable, insoluble structural inclusions. As noted above, however, structural 
inclusions have become something of a nuisance, distracting attention from the putative real culprits—
soluble, toxic Aβ or phospho-tau intermediates, themselves invisible as they apparently attack an 
ultrastructural entity, the synapse, in a molecular process that is further unamenable to direct 
observation, but rather inferred from electrophysiology or behavioral studies involving the pulling of 
levers by rats and so forth. In this respect, recent turns toward cell signaling aberrations caused by Aβ 
oligomers is strategic [3], since cell signaling is more readily measured than an attack on a   
synapse in vivo.  
Oxidative damage is thus in the same category as favored hypotheses related to Aβ and tau, in that 
it is a biochemical phenomenon that cannot be directly observed. It may be argued, however, that the 
oxidative stress hypothesis offers several conceptual advantages. First, it is well documented that 
oxidative stress increases with advancing age, in parallel with the strict relationship between age and 
neurodegenerative disease, along with the general decline in antioxidant defenses [4]. In contrast, Aβ Int. J. Mol. Sci. 2009, 10                 
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synthesis occurs throughout life and, to date, no mechanism has been offered to explain the absence of 
amyloidogenesis, over multiple decades, resulting from a putative amyloidogenic cleavage cascade, 
even in the presence of pathogenic mutations or an extra copy of chromosome 21. Some external factor 
must exist that has yet to be characterized, for amyloid fibrils, or even amyloid oligomers, to exert a 
deleterious effect only after years of structurally and functionally normal cellular metabolism. Second, 
oxidative stress has pleiotropic effects; every category of macromolecule is affected, including 
membrane lipids, proteins, carbohydrates, and nucleic acids, both DNA and RNA [53,54]. Third, 
whereas direct damage from unpaired electrons cannot be visualized, oxidative stress results in specific 
molecular adducts, such as Michael adducts hydroxynonenal, malondialdehyde, advanced glycation 
adducts pentosidine and pyrraline, heterogeneous adducts such as carboxymethyllysine and 
nitrotyrosine, and nucleic acid oxidation products such as 8-hydroxyguanosine [55-58]. Such products 
can be identified and directly measured.  
 
4.1. Evidence for oxidative stress 
 
AD increases exponentially throughout life, being non-existent during youth, rare in the middle 
aged, and common in the elderly [59]. Clearly, age is a risk factor for AD. Like other organ systems, 
the brain endures a cumulative burden of oxidative damage, which is a universal feature of aging. 
Moreover, the brain is especially vulnerable to oxidative stress because of its high content of easily 
peroxidizable fatty acids, high oxygen consumption, and relative paucity of antioxidant enzymes 
compared with other organs [60-62].  
Germline mutations leading to familial early onset AD are also oxidative stress-causing mutations. 
Increased vulnerability to oxidative stress-induced cell death and/or reduced antioxidant defenses have 
been demonstrated in: i) cell lines expressing mutant AβPP, PS1, and PS2 [63-66]; ii) transgenic mice 
expressing mutant AβPP or PS1, and knockout mice expressing mutant human PS1 [67-74]; iii) 
fibroblasts and lymphoblasts from patients with familial early onset AD with either PS1 or AβPP 
mutations [75]; iv) cerebral cortex obtained at autopsy from patients with AβPP and PS1 mutations 
[76,77]; and v) patients with one or both ApoE ε4 alleles [78]. In vitro, ApoE ε4 status shows relative 
increases in oxidative damage, whereas ApoE ε2 status shows relatively decreased oxidative   
damage [79].  
Multiple AD risk factors are associated with an increase in production and propagation of reactive 
oxygen species, including traumatic brain injury, hypertensive vascular disease, diabetes mellitus, 
hypercholesterolemia, and hyperhomocysteinemia [80-84]. Environmental and lifestyle related risk 
factors for AD include aluminum, smoking, high calorie intake, lack of exercise, and lack of 
intellectual activity [85-88], each of which are associated with oxidative stress and/or reduced 
antioxidant defenses [89-94]. Decreased risk of AD is further associated with a number of factors 
including vitamin C and E, estrogen, non-steroidal anti-inflammatory drugs, statins, omega-3 
polyunsaturated fatty acids, and red wine [95-100], each of which have antioxidant properties [101-
105]. Furthermore, caloric restriction, exercise, and intellectual activity have been shown to promote 
neuronal survival through enhancement of endogenous antioxidant defenses in experimental   
animals [106]. 
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4.2. Oxidative stress is an early event 
 
The early involvement of oxidative stress in AD is demonstrated by recent studies on cell culture 
models, transgenic animal models, postmortem brains, and biologic fluids from subjects with AD, 
MCI, and Down syndrome. Using an in situ approach to identify markers of nucleic acid and protein 
oxidation in human brain, we found that oxidative damage is more pronounced in AD subjects with 
lesser amounts of Aβ deposition or AD subjects with shorter disease duration [107]. Furthermore, we 
found that oxidative damage precedes Aβ deposition in brain tissue from Down syndrome, a putative 
model of AD with predictable neuropathological progression over time [108]. These findings are 
consistent with the increased nucleic acid oxidation in the brain and in cerebrospinal fluid from AD 
subjects, in which the shorter the disease duration, the greater the oxidative damage [109-111] . 
Moreover, individuals with MCI or very mild AD show: i) increased levels of lipid peroxidation and 
nucleic acid oxidation in postmortem brain tissue [112,113]; ii) increased levels of lipid peroxidation 
and nucleic acid oxidation in cerebrospinal fluid, plasma, urine, and peripheral leukocytes [114,115]; 
and iii) decreased levels of plasma antioxidants and total plasma antioxidant capacity [116,117]. 
Upregulation of heme oxygenase-1, a sensitive marker of oxidative stress, is observed in astroglial 
cells in postmortem brains of AD and MCI [118].  
This human data is supported by experimental studies using cell culture and transgenic animal 
models of AD. Increased lipid peroxidation and protein oxidation, and decreased Cu/Zn superoxide 
dismutase activity, precede Aβ deposition or Aβ fibril formation in transgenic mice and C. elegans 
models of AD amyloidosis [69,119-121]. Oxidative stress induces intracellular Aβ accumulation and 
tau phosphorylation in cell cultures [122-124], and vitamin E reduces Aβ and tau lesions in transgenic 
animals [125,126]. Further dietary copper stabilizes brain Cu/Zn superoxide dismutase activity and 
reduces Aβ deposition in AβPP transgenic mice [127]. AβPP mutant mice crossed with manganese 
SOD heterozygous knockout mice show increased Aβ plaque deposition in the brain [128]. The early 
involvement of oxidative stress in the pathologic cascade of AD is likely to be closely associated with 
other key features of AD such as metabolic dysfunction, mitochondrial dysfunction, metal 
dysregulation, and cell cycle dysregulation [129]. Mitochondrial abnormalities are proving to be a 
substantial source and recipient of oxidative stress events that likely are responsible for many of the 
pathological correlates of the cognitive deficiencies including synaptic loss [130]. Aβ and the AβPP 
molecule both affect mitochondria form and function in cellular and animal models suggesting 
mitochondria as a key player in the first stages of neuronal dysfunction [131-133]. In fact, all these 
features are observed as early stage events of AD which are shown in human [134-137] and transgenic 
animal models [131,138-140]. In short, oxidative stress is not only an upstream event, but also has 
been shown to play a fundamental, direct role in the pathogenesis of AD by a variety of mechanisms.  
 
4.3. Neuropathology equals neuroprotection 
 
As the neuroscience community shifts hypotheses in the direction of soluble intermediates, it is 
becoming more apparent that the pathology of AD represents effect rather than cause, or response to 
injury rather than injury per se. The presence of significant plaque pathology in the absence of 
cognitive deficits in humans as noted above, and the absence of neuronal loss in transgenic mice Int. J. Mol. Sci. 2009, 10                 
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despite prodigious accumulations of Aβ, underscores the secondary nature of Aβ in disease, and a 
likely fundamental role in antioxidant neuroprotection.  
Importantly, whereas high concentrations of Aβ in the micromolar range can lead to oxidative stress 
in various in vitro systems, it is apparent from cell, animal, and human studies that oxidative stress 
precedes Aβ deposition [69,119,120,126-128]. Moreover, increased density of Aβ plaques is 
associated with decreased levels of nucleic acid oxidation in postmortem brain tissue from familial and 
sporadic AD subjects as well as Down syndrome [76,107,108]. These findings further indicate that the 
process of Aβ plaque formation is linked to protection against oxidative stress. Recently, in vitro and 
in vivo studies have demonstrated an antioxidant activity of Aβ. Monomeric Aβ40 and Aβ42 have been 
shown to protect cultured neurons from iron and copper-induced oxidative toxicity [141]. In addition, 
co-injection of iron and Aβ42 into rat cerebral cortex is significantly less toxic than infection of iron 
alone [142]. Moreover, addition of physiological concentrations (low nanomolar range) of Aβ40 and 
Aβ42 has been shown to protect lipoproteins from oxidation in cerebrospinal fluid and plasma [143]. 
These Aβ peptides fail to prevent metal independent oxidation and Aβ25-35 lacking the metal binding 
site located in the N-terminal domain (histidine at positions 6, 13, and 14, and tyrosine at position 10) 
is less effective at inhibiting oxidation. Therefore, it is likely that the mechanism by which Aβ inhibits 
oxidation is through binding metal ions, as a form of free radical “sponge” [143]. Pathological lesions, 
therefore, are a fundamental indicator of neuroprotection and specifically protect brain against heavy 
metal catalyzed free radical injury.  
The antioxidant role of Aβ may also apply to tau. Cellular, animal, and human studies suggest that, 
like Aβ deposition, oxidative stress precedes neurofibrillary tangle formation [108,124,125]. Oxidative 
stress activates several kinases, including glycogen synthase kinase-3 and mitogen-activated protein 
kinases, which are activated in AD and capable of phosphorylating tau. Once phosphorylated, tau 
becomes vulnerable to oxidative modification, formation of intra- and intermolecular crosslinks, and 
aggregation into filaments (reviewed in [144]). Neurofibrillary tangle formation therefore is 
accelerated by oxidative stress, which is consistent with evidence of induction of the antioxidant 
enzyme, heme oxygenase-1 [145]. Furthermore, in postmortem AD tissue, nucleic acid oxidation is 
decreased in neurofibrillary tangle-containing neurons compared to vulnerable neurons without 
neurofibrillary tangles [107]. Although the mechanism by which neurofibrillary tangle formation 
potentially reduces oxidative stress is unknown, redox active iron accumulation within neurofibrillary 
tangles has been demonstrated [146], suggesting, in analogy to Aβ plaques, that neurofibrillary tangles 
are a sink for heavy metal derived free radicals.  
In short, recent data with respect to Aβ and tau suggest insoluble pathological lesions, rather than 
being toxic as previously thought, are non-toxic responses to the underlying disease process that, in 
essence, are indicators of the hosts attempt at antioxidant neuroprotection.  
 
5. Conclusions 
 
Current theories pertaining to the molecular pathogenesis of AD encompass copious and 
sophisticated data, but nevertheless have their origin, or foundation, in hallmark pathological lesions 
described more than a century ago. Once considered manifestations of neurotoxicity, these same 
lesions are now considered insoluble epiphenomena that only distract from upstream Int. J. Mol. Sci. 2009, 10                 
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pathophysiological events involving soluble, toxic intermediates and the synapse, events ironically that 
cannot be directly observed. For better or worse, the lesions of origin, in essence the microscopic 
neuropathology, are now discarded in the pellet of the ultracentrifuge tube, during the course of study 
of the molecular pathogenesis of AD. Based on considerable evidence, however, we favor the few that 
pathological lesions can be tied to molecular pathogenesis on the basis of disease expression, or a host 
response, that is fundamentally adaptive over a long period of time, to combat the adverse pleiotropic 
effects of oxidative damage. So-called toxic intermediates may well be an extension of this productive 
host response and should be considered for therapeutic targeting only with considerable care. The time 
for a paradigm shift that targets the more expansionist approach of oxidative stress, rather than 
reductionist approaches centered on singular small molecules, may be warranted, and in fact overdue.  
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